FDA Admits Antidepressants Can CAUSE Suicide?!

They finally had to admit it…

After decades of denial and buried data, the FDA slapped a BLACK BOX WARNING on antidepressants—the most severe alert short of banning them.

Why? Because antidepressants can trigger suicidal thoughts and behaviors—especially in the young, the vulnerable, and yes, even in millions of unsuspecting adults.

Not “maybe.” Not “could.” They can—and do.

This isn’t brand-new info. The evidence started stacking up in 1991, but it took the FDA 13 years to act:

• 1991: FDA held a public meeting about “abnormal behaviors” in Prozac patients.
• 2004: FDA finally issued a public health advisory.
• 2004: Black box warning for pediatric
• 2007: Warning extended to ages up to 24.

Patients and families had been sounding the alarm since day one—but Big Pharma buried them until they couldn’t deny anymore.

Behind those headlines: real people suffering and dying.

Think antidepressants are harmless? Think again.

Check the official FDA/DailyMed label for duloxetine (Cymbalta). Right up top—Black Box Warning:

“Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants… Monitor for worsening and emergence of suicidal thoughts and behaviors.”

This isn’t hidden in fine print—it’s the FDA’s strongest warning, second only to pulling the drug entirely.

And it’s not just anecdotal. Large-scale studies have documented it:

Study	Findings
Finnish cohort	15,390 patients had increased suicide attempts while on SSRIs.
Ontario elderly study	1.2 million showed spiked suicide risk in the first month of SSRI use.
UK database	159,810 patients revealed elevated suicidal behavior—especially in days 1–9.
Meta-analysis	87,650 subjects confirmed SSRIs linked to suicide attempts.

Science has explained how safe drugs turn lethal:

1. “Energize Before Healing” – Energy returns before mood improves—giving suicidal thoughts fuel to act.
2. Akathisia – Intense restlessness that drives desperate people toward extreme measures.
3. Paradoxical reactions
4. Brain chaos – SSRIs alter electrical brain patterns, scrapping impulse control and decision-making.

The first “evidence” clearing Prozac came from Eli Lilly—the manufacturer—using their own data.

They ran the studies. They interpreted the results. And guess what? No blame.

Then dozens of ghostwritten articles followed—masking adverse events and glorifying safety.

No wonder the suicides kept piling up.

When the FDA finally issued the boxed warning, guess what happened?

Prescription rates plunged—31% among teens, 24.3% among 18–29-year-olds within a year—but mental health crisis didn’t pause.

Instead, suicide attempts via psychotropic overdose skyrocketed by 21.7% in teens, 33.7% in young adults.

Big Pharma wins either way: When they advertise, they sell drugs. When they warn, they claim depression worsens without them.

Red flag symptoms during early treatment or dose changes:

• Agitation or restlessness
• Anxiety or panic
• Insomnia
• New aggression
• Suicidal thoughts

Highest-risk windows:

• First 9 days
• First month
• Any time doses are changed
• Especially under 25 years old

Stay alert. Stay vocal. This is your life.

Big Pharma doesn’t want you to know: Mental wellness can be supported naturally, without risking your life.

• John’s Wort – as effective as SSRIs in mild-to-moderate depression.
• Omega-3s (EPA) – reduce symptoms and improve mood stability.
• Vitamin D3 – low levels linked to depression and low mood.
• B-complex – essential for brain chemistry and neurotransmitter production.
• Magnesium – eases stress, calms the nervous system.
• Regular movement – proven to outperform drugs for many individuals.

These don’t come with warnings about suicide—they come with improved wellbeing.

The FDA finally admitted it: Antidepressants can CAUSE suicide. Not in theory—in practice, especially in young users starting treatment.

It shouldn’t have taken 16 years and countless tragedies—but now the truth is out. Are you going to accept it?

Ask the tough questions. Demand transparency. Don’t let a one-line warning bury your life.

Because when medicine kills, the only real cure is awareness.

Protect yourself and those you love—the only person looking out for you is you.

In Your Corner,

Dr. Allan Spreen

In Case You Missed It

• What Your Speech Might Be Saying About Your Brain
• The One Number That Predicts How You’re Aging (It’s NOT Your Weight)
• The Hidden Brain Hazard in Your Bedroom Light
• A Cough Syrup for Parkinson’s Dementia? Not So Fast
• The Cancer Surge You Haven’t Heard About (But Should!)
• The Vaccine Ingredient Sparking Fresh Controversy
• The Silent Heart Risk for Women Over 45

Sources:

• Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ, 330(7488), 396. https://doi.org/10.1136/bmj.330.7488.396
• Reeves, R. R., & Ladner, M. E. (2010). Antidepressant-induced suicidality: An update. CNS Neuroscience & Therapeutics, 16(4), 227–234. https://doi.org/10.1111/j.1755-5949.2010.00160.x
• Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., … & Hammad, T. A. (2009). Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, b2880. https://doi.org/10.1136/bmj.b2880
• S. Food and Drug Administration. (2004, October 15). Public health advisory: Suicidality in children and adolescents being treated with antidepressant medications. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications
• Gibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., Erkens, J. A., … & Mann, J. J. (2007). Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry, 164(9), 1356–1363. https://doi.org/10.1176/appi.ajp.2007.07030454
• Lu, C. Y., Zhang, F., Lakoma, M. D., Madden, J. M., Rusinak, D., Penfold, R. B., … & Soumerai, S. B. (2014). Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: Quasi-experimental study. BMJ, 348, g3596. https://doi.org/10.1136/bmj.g3596
• Glenmullen, J. (2000). Prozac backlash: Overcoming the dangers of Prozac, Zoloft, Paxil, and other antidepressants with safe, effective alternatives. Simon & Schuster.
• Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet, 363(9418), 1341–1345. https://doi.org/10.1016/S0140-6736(04)16043-1